As of Mar 22
| -1.05 / -5.59%|
The 7 analysts offering 12-month price forecasts for Momenta Pharmaceuticals Inc have a median target of 16.00, with a high estimate of 18.00 and a low estimate of 10.00. The median estimate represents a -9.86% decrease from the last price of 17.75.
The current consensus among 7 polled investment analysts is to Hold stock in Momenta Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.